Mohammad Hojjat-Farsangi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2676899/publications.pdf

Version: 2024-02-01

118 papers	3,624 citations	147801 31 h-index	161849 54 g-index
122 all docs	122 docs citations	122 times ranked	5419 citing authors

#	Article	IF	Citations
1	Nanoparticles and targeted drug delivery in cancer therapy. Immunology Letters, 2017, 190, 64-83.	2.5	374
2	The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. Biomedicine and Pharmacotherapy, 2018, 108, 1415-1424.	5.6	201
3	Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies. International Journal of Molecular Sciences, 2014, 15, 13768-13801.	4.1	174
4	Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer. Journal of Cellular Physiology, 2018, 233, 2032-2057.	4.1	116
5	CD73 as a potential opportunity for cancer immunotherapy. Expert Opinion on Therapeutic Targets, 2019, 23, 127-142.	3.4	102
6	Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy. Tumor Biology, 2015, 36, 5727-5742.	1.8	96
7	The imbalance of Th17/Treg axis involved in the pathogenesis of preeclampsia. Journal of Cellular Physiology, 2019, 234, 5106-5116.	4.1	91
8	Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells. Leukemia, 2012, 26, 1348-1355.	7.2	86
9	The receptor tyrosine kinase ROR1 â€“ An oncofetal antigen for targeted cancer therapy. Seminars in Cancer Biology, 2014, 29, 21-31.	9.6	85
10	Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer. Prostaglandins and Other Lipid Mediators, 2019, 144, 106338.	1.9	79
11	Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies. Leukemia and Lymphoma, 2013, 54, 843-850.	1.3	67
12	Blockage of immune checkpoint molecules increases Tâ€cell priming potential of dendritic cell vaccine. Immunology, 2020, 159, 75-87.	4.4	67
13	Mechanisms of tumor cell resistance to the current targeted-therapy agents. Tumor Biology, 2016, 37, 10021-10039.	1.8	60
14	Downregulation of A2AR by siRNA loaded PEG-chitosan-lactate nanoparticles restores the T cell mediated anti-tumor responses through blockage of PKA/CREB signaling pathway. International Journal of Biological Macromolecules, 2019, 133, 436-445.	7.5	58
15	CDK1 in Breast Cancer: Implications for Theranostic Potential. Anti-Cancer Agents in Medicinal Chemistry, 2020, 20, 758-767.	1.7	57
16	Antiâ€angiogenic effects of CD73â€specific siRNAâ€loaded nanoparticles in breast cancerâ€bearing mice. Journal of Cellular Physiology, 2018, 233, 7165-7177.	4.1	56
17	Silencing of IL-6 and STAT3 by siRNA loaded hyaluronate-N,N,N-trimethyl chitosan nanoparticles potently reduces cancer cell progression. International Journal of Biological Macromolecules, 2020, 149, 487-500.	7.5	56
18	The Tyrosine Kinase Receptor ROR1 Is Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) Cells. PLoS ONE, 2013, 8, e78339.	2.5	54

#	Article	IF	Citations
19	Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells. PLoS ONE, 2013, 8, e61167.	2.5	50
20	Increased Frequency of CD8⁺and CD4⁺Regulatory T Cells in Chronic Lymphocytic Leukemia: Association with Disease Progression. Cancer Investigation, 2013, 31, 121-131.	1.3	49
21	Altered Tâ€cell subpopulations in recurrent pregnancy loss patients with cellular immune abnormalities. Journal of Cellular Physiology, 2019, 234, 4924-4933.	4.1	45
22	Cernunnos influences human immunoglobulin class switch recombination and may be associated with B cell lymphomagenesis. Journal of Experimental Medicine, 2012, 209, 291-305.	8.5	44
23	Berberine: A novel therapeutic strategy for cancer. IUBMB Life, 2020, 72, 2065-2079.	3.4	44
24	The role of DEADâ€box RNA helicase p68 (DDX5) in the development and treatment of breast cancer. Journal of Cellular Physiology, 2019, 234, 5478-5487.	4.1	41
25	Cancer associated fibroblasts as novel promising therapeutic targets in breast cancer. Pathology Research and Practice, 2020, 216, 152915.	2.3	39
26	Application of nanomedicine for crossing the bloodâ€“brain barrier: Theranostic opportunities in multiple sclerosis. Journal of Immunotoxicology, 2016, 13, 603-619.	1.7	38
27	Altered Th17/Treg ratio as a possible mechanism in pathogenesis of idiopathic membranous nephropathy. Cytokine, 2021, 141, 155452.	3.2	38
28	Oxidative stress, inflammatory settings, and microRNA regulation in the recurrent implantation failure patients with metabolic syndrome. American Journal of Reproductive Immunology, 2019, 82, e13170.	1.2	37
29	S1PR1 as a Novel Promising Therapeutic Target in Cancer Therapy. Molecular Diagnosis and Therapy, 2019, 23, 467-487.	3.8	37
30	Oncostatin M: A mysterious cytokine in cancers. International Immunopharmacology, 2021, 90, 107158.	3.8	35
31	Variation in WNT genes expression in different subtypes of chronic lymphocytic leukemia. Leukemia and Lymphoma, 2009, 50, 2061-2070.	1.3	34
32	E2 ubiquitin-conjugating enzymes in cancer: Implications for immunotherapeutic interventions. Clinica Chimica Acta, 2019, 498, 126-134.	1.1	33
33	PD-L1/PD-1 axis as a potent therapeutic target in breast cancer. Life Sciences, 2020, 247, 117437.	4.3	33
34	The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies. British Journal of Haematology, 2015, 169, 455-458.	2.5	32
35	Fc receptorâ€like 1â€“5 molecules are similarly expressed in progressive and indolent clinical subtypes of Bâ€cell chronic lymphocytic leukemia. International Journal of Cancer, 2008, 123, 2113-2119.	5.1	30
36	Induction of IgM, IgA and IgE Antibodies in Colorectal Cancer Patients Vaccinated with a Recombinant CEA Protein. Journal of Clinical Immunology, 2012, 32, 855-865.	3.8	30

#	Article	IF	Citations
37	First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells. Leukemia, 2018, 32, 2291-2295.	7.2	30
38	Concomitant blockade of A2AR and CTLAâ€4 by siRNAâ€loaded polyethylene glycolâ€chitosanâ€alginate nanoparticles synergistically enhances antitumor Tâ€cell responses. Journal of Cellular Physiology, 2020, 235, 10068-10080.	4.1	30
39	Nanomedicine for improvement of dendritic cell-based cancer immunotherapy. International Immunopharmacology, 2020, 83, 106446.	3.8	30
40	Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia. Cancer Science, 2009, 100, 2346-2353.	3.9	29
41	Dimethyl fumarate: Regulatory effects on the immune system in the treatment of multiple sclerosis. Journal of Cellular Physiology, 2019, 234, 9943-9955.	4.1	29
42	Assessment of the immune system in 55 Iranian patients with vitiligo. Journal of the European Academy of Dermatology and Venereology, 2005, 19, 706-711.	2.4	28
43	Novel and emerging targeted-based cancer therapy agents and methods. Tumor Biology, 2015, 36, 543-556.	1.8	28
44	Intrauterine administration of autologous hCG- activated peripheral blood mononuclear cells improves pregnancy outcomes in patients with recurrent implantation failure; A double-blind, randomized control trial study. Journal of Reproductive Immunology, 2020, 142, 103182.	1.9	28
45	A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib. PLoS ONE, 2018, 13, e0198038.	2.5	27
46	Metabolic syndrome mediates proinflammatory responses of inflammatory cells in preeclampsia. American Journal of Reproductive Immunology, 2019, 81, e13086.	1.2	27
47	IL-10-producing B cells play important role in the pathogenesis of recurrent pregnancy loss. International Immunopharmacology, 2020, 87, 106806.	3.8	27
48	Application of Emerging Plant-Derived Nanoparticles as a Novel Approach for Nano-Drug Delivery Systems. Immunological Investigations, 2022, 51, 1039-1059.	2.0	27
49	The skewed balance between Tregs and Th17 in chronic lymphocytic leukemia. Future Oncology, 2015, 11, 1567-1582.	2.4	25
50	Toxicity of Saffron Extracts on Cancer and Normal Cells: A Review Article. Asian Pacific Journal of Cancer Prevention, 2020, 21, 1867-1875.	1.2	25
51	Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia. Tumor Biology, 2016, 37, 11947-11957.	1.8	24
52	Molecular Profiling of Pheochromocytoma and Abdominal Paraganglioma Stratified by the PASS Algorithm Reveals Chromogranin B as Associated With Histologic Prediction of Malignant Behavior. American Journal of Surgical Pathology, 2019, 43, 409-421.	3.7	24
53	Smac mimetics as novel promising modulators of apoptosis in the treatment of breast cancer. Journal of Cellular Biochemistry, 2019, 120, 9300-9314.	2.6	23
54	Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 29, 102240.	3.3	23

#	Article	IF	Citations
55	Tâ€cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer. IUBMB Life, 2021, 73, 726-738.	3.4	23
56	Blockade of CD73 using siRNA loaded chitosan lactate nanoparticles functionalized with TAT-hyaluronate enhances doxorubicin mediated cytotoxicity in cancer cells both in vitro and in vivo. International Journal of Biological Macromolecules, 2021, 186, 849-863.	7.5	23
57	Expression Profile of Galectin-1 and Galectin-3 Molecules in Different Subtypes of Chronic Lymphocytic Leukemia. Cancer Investigation, 2010, 28, 717-725.	1.3	22
58	Polymorphism of Foxp3 gene affects the frequency of regulatory T cells and disease activity in patients with rheumatoid arthritis in Iranian population. Immunology Letters, 2018, 204, 16-22.	2.5	22
59	Codelivery of BV6 and anti-IL6 siRNA by hyaluronate-conjugated PEG-chitosan-lactate nanoparticles inhibits tumor progression. Life Sciences, 2020, 260, 118423.	4.3	22
60	Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression. Life Sciences, 2021, 275, 119369.	4.3	22
61	Ibrutinib-A double-edge sword in cancer and autoimmune disorders. Journal of Drug Targeting, 2016, 24, 373-385.	4.4	21
62	Recent advances in targeting mTOR signaling pathway using small molecule inhibitors. Journal of Drug Targeting, 2017, 25, 189-201.	4.4	21
63	Analysis of the immunoglobulin heavy chain variable region gene expression in Iranian patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2007, 48, 109-116.	1.3	20
64	Differential regulation of B-cell proliferation by IL21 in different subsets of chronic lymphocytic leukemia. Cytokine, 2013, 62, 439-445.	3.2	20
65	ROR1 is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells. Biomedicines, 2020, 8, 170.	3.2	19
66	Tumor associated macrophages in the molecular pathogenesis of ovarian cancer. International Immunopharmacology, 2020, 84, 106471.	3.8	18
67	EP4 receptor as a novel promising therapeutic target in colon cancer. Pathology Research and Practice, 2020, 216, 153247.	2.3	17
68	Telomere length and expression of human telomerase reverse transcriptase splice variants in chronic lymphocytic leukemia. Experimental Hematology, 2013, 41, 615-626.	0.4	16
69	T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile. Cancer Immunology, Immunotherapy, 2013, 62, 51-63.	4.2	16
70	TIGIT and CD155 as Immune-Modulator Receptor and Ligand on CD4⁺T cells in Preeclampsia Patients. Immunological Investigations, 2022, 51, 1023-1038.	2.0	15
71	Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances. Journal of Drug Targeting, 2016, 24, 192-211.	4.4	14
72	Human leukocyte antigen class II allele association to disease progression in Iranian patients with chronic lymphocytic leukemia. Human Immunology, 2008, 69, 666-674.	2.4	13

#	Article	IF	Citations
73	Ligation of human Fc receptor likeâ€2 by monoclonal antibodies downâ€regulates Bâ€cell receptorâ€mediated signalling. Immunology, 2014, 143, 341-353.	4.4	12
74	An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein. Human Vaccines and Immunotherapeutics, 2021, 17, 92-97.	3.3	12
75	Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia. PLoS ONE, 2015, 10, e0142310.	2.5	12
76	Promising immunotherapy: Highlighting cytokineâ€induced killer cells. Journal of Cellular Biochemistry, 2019, 120, 8863-8883.	2.6	11
77	Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung. Cell Death and Disease, 2021, 12, 577.	6.3	11
78	Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy. Current Drug Targets, 2016, 17, 1687-1703.	2.1	11
79	Construction and characterization of a new chimeric antibody against HER2. Immunotherapy, 2013, 5, 703-715.	2.0	10
80	Construction of a hepatitis B virus neutralizing chimeric monoclonal antibody recognizing escape mutants of the viral surface antigen (HBsAg). Antiviral Research, 2017, 144, 153-163.	4.1	10
81	The Association between Inflammatory Cytokines and miRNAs with Slow Coronary Flow Phenomenon. Iranian Journal of Allergy, Asthma and Immunology, 2020, 19, 56-64.	0.4	10
82	Simultaneous silencing of the A2aR and PD-1 immune checkpoints by siRNA-loaded nanoparticles enhances the immunotherapeutic potential of dendritic cell vaccine in tumor experimental models. Life Sciences, 2022, 288, 120166.	4.3	10
83	Early stage evaluation of colon cancer using tungsten disulfide quantum dots and bacteriophage nano-biocomposite as an efficient electrochemical platform. Cancer Nanotechnology, 2022, 13, .	3.7	10
84	Exosome: From leukemia progression to a novel therapeutic approach in leukemia treatment. BioFactors, 2020, 46, 698-715.	5.4	9
85	Sero-Epidemiological Study of Hepatitis E Virus among Thalassemia as High Risk Patients: A Cross-Sectional Survey in Jahrom, Southern, Iran. Global Journal of Health Science, 2015, 8, 245.	0.2	8
86	Comparative expression profile of orphan receptor tyrosine kinase ROR1 in Iranian patients with lymphoid and myeloid leukemias. Avicenna Journal of Medical Biotechnology, 2011, 3, 119-25.	0.3	8
87	Identification of genes and miRNAs associated with angiogenesis, metastasis, and apoptosis in colorectal cancer. Gene Reports, 2020, 18, 100552.	0.8	7
88	Lack of Association Between rs17568 Polymorphism in OX40 Gene and Myocardial Infarction, Southern of Iran. Global Journal of Health Science, 2015, 8, 41.	0.2	6
89	Dishevelled Proteins of Wnt Signaling Pathways Are Highly Expressed in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 4583-4583.	1.4	6
90	Influence of Pattern Recognition Receptor Ligands on Induction of Innate Immunity and Control of Hepatitis B Virus Infection. Viral Immunology, 2021, 34, 531-541.	1.3	5

#	Article	IF	Citations
91	Abstract 4770: Anti-ROR1 monoclonal antibodies induce apoptosis in pancreatic cancer cells via the PI3-kinase/AKT/mTOR pathway. Cancer Research, 2014, 74, 4770-4770.	0.9	5
92	Targeting the Receptor Tyrosine Kinase ROR1 by Small Molecules. Handbook of Experimental Pharmacology, 2021, 269, 75-99.	1.8	5
93	Frequency analysis of HLA class I alleles in Iranian patients with progressive and non-progressive chronic lymphocytic leukemia. Human Immunology, 2014, 75, 170-175.	2.4	4
94	Association of Tumor Growth Factor-Î² and Interferon-Î³ Serum Levels With Insulin Resistance in Normal Pregnancy. Global Journal of Health Science, 2015, 8, 25.	0.2	4
95	Immunoreactivity pattern of monoclonal antibodies against Hepatitis B vaccine with global Hepatitis B virus genotypes. Clinica Chimica Acta, 2020, 510, 203-210.	1.1	4
96	A new class of compound for pancreatic carcinoma targeting the tyrosine kinase receptor (TKR) ROR1.. Journal of Clinical Oncology, 2014, 32, e13561-e13561.	1.6	4
97	A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinibâ€resistant ROR1⁺ CLL cells. EJHaem, 2021, 2, 498-502.	1.0	3
98	ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells. Blood, 2019, 134, 5312-5312.	1.4	3
99	Effect of ROR1-targeting small molecules on chronic lymphocytic leukemia (CLL) cells.. Journal of Clinical Oncology, 2012, 30, 6557-6557.	1.6	3
100	Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells. PLoS ONE, 2018, 13, e0192839.	2.5	3
101	Kisspeptin serum levels in acute myocardial infarction patients and healthy individuals. Biomedical Research and Therapy, 2018, 5, 2111-2118.	0.6	3
102	ROR1 Isoforms Are Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) - a Survival Factor for CLL Cells. Blood, 2011, 118, 1778-1778.	1.4	2
103	First-in-Class ROR1 Small Molecule Inhibitor (KAN0439834) Downregulated Wnt-Canonical and Non-Canonical Signaling Pathways and Induced Apoptosis of CLL Cells. Blood, 2015, 126, 2912-2912.	1.4	2
104	Apoptosis induction mediated through PI3-kinase/AKT/mTOR pathway using anti-ROR1 monoclonal antibody in chronic lymphocytic leukemia cells.. Journal of Clinical Oncology, 2013, 31, 7087-7087.	1.6	2
105	First generation of a small chemical molecule ROR1 RTK tyrosine kinase inhibitor. Annals of Oncology, 2016, 27, vi530.	1.2	1
106	Ror1 Targeting Monoclonal Antibodies Induced Apoptosis of Chronic Lymphocytic Leukemia Cellsâ€“ A Potential Novel Therapeutic Approach. Blood, 2010, 116, 916-916.	1.4	1
107	Monoclonal Antibody Against ROR1 in Chronic Lymphocytic Leukemia Cells Induced Apoptosis Via PI3-Kinase/AKT/CREB Pathway. Blood, 2012, 120, 1769-1769.	1.4	1
108	A new class of anti-cancer drugs targeting the tyrosine kinase receptor ROR1 in CLL.. Journal of Clinical Oncology, 2015, 33, 8556-8556.	1.6	1

#	Article	IF	Citations
109	9209 POSTER Unbalanced Frequency of Regulatory T Cells in Different Subsets of Chronic Lymphocytic Leukemia. European Journal of Cancer, 2011, 47, S642.	2.8	0
110	1.7 Telomere Length and Expression of Human Telomerase Reverse Transcriptase Splice Variants in Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S145.	0.4	0
111	162 Investigation of TLR7/8 and 9 Agonists and CD40-ligand Costimulation on EBV Transformation of B Cells of Chronic Lymphocytic Leukemia. European Journal of Cancer, 2012, 48, S39.	2.8	0
112	P47.10 Predicting ROR1/BCL2 Combination Targeted Therapy of Small Cell Carcinoma of the Lung. Journal of Thoracic Oncology, 2021, 16, S496.	1.1	0
113	Patients with Chronic Lymphocyte Leukemia (CLL) Have Naturally Occurring Antibodies Against the Receptor Tyrosine Kinase (ROR1). Blood, 2011, 118, 1771-1771.	1.4	0
114	Phosphorylation of Receptor Tyrosine Kinase ROR1 At Tyrosine 641, 646 and Serine 652 residues Might Be of Importance for the Survival of CLL Leukemic Cells. Blood, 2012, 120, 3885-3885.	1.4	0
115	Construction and characterization of a new chimeric antibody against HER2. Frontiers in Immunology, 0, 4, .	4.8	0
116	Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells.. Journal of Clinical Oncology, 2013, 31, e22198-e22198.	1.6	0
117	Somatic Mutation in Immunoglobulin Gene Variable Region in Patients With Chronic Lymphoid Leukemia and Its Influence on Disease Prognosis. Middle East Journal of Rehabilitation and Health Studies, 2016, 3, .	0.4	0
118	Diffuse Large B Cell Lymphoma (DLBCL) Expresses ROR1 and a ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Tumor Cells. Blood, 2019, 134, 2565-2565.	1.4	0